Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives $88.25 Average PT from Analysts
Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) has been given a consensus recommendation of “Buy” by the five analysts that are covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have covered the stock in the last […]
Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) has been given a consensus recommendation of “Buy” by the five analysts that are covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have covered the stock in the last […]
